RGRené Gaupmann

René Gaupmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


René Gaupmann has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Graf

    Medical University of Vienna

    1 shared publication
  • Barbara Bohle

    Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    1 shared publication
  • Christina Bannert

    Division of Paediatric Pulmonology, Allergology and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics Medical University of Vienna Vienna Austria

    1 shared publication
  • Eleonora Dehlink

    Division of Paediatric Pulmonology, Allergology and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics Medical University of Vienna Vienna Austria

    1 shared publication
  • Hilal Demir

    Institute of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

    1 shared publication
  • Justyna Sieber

    Division of Paediatric Pulmonology, Allergy and Endocrinology, Department of Paediatrics and Adolescent Medicine, Comprehensive Centre of Paediatrics Medical University of Vienna Vienna Austria

    1 shared publication

Latest Publications

  • Open Access

    Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children

    by Varsha Dwivedi, Klara Schmidthaler, Hilal Demir, Justyna Sieber, René Gaupmann, Livia Mia Gona‐Höpler, Christina Bannert, Saskia Gruber, Eleonora Dehlink, Thomas Eiwegger, et al.

    Background: Sublingual allergen immunotherapy (SLIT) is an effective treatment for immunoglobulin (Ig)E‐mediated allergies. Its success is associated with allergen‐specific (s)IgG, which blocks IgE‐mediated mechanisms. Preventive effects of SLIT in children before allergy‐symptom onset remain largely unexplored. Methods: A randomized trial was conducted between October 06, 2017 and December 15, 2022, which included house dust mite (HDM)‐sensitized preschool children (aged 3–5 years) showing no allergy symptoms. They were randomized (2:2 blocks) to HDM‐SLIT (300 index of reactivity/day, Staloral) or placebo solution for 2 years. Children receiving > 4 months of treatment were included in the analysis. Primary objective of the study was to compare the groups for change in major HDM allergen‐Der p 1‐sIgG levels from baseline to end of treatment (EOT). Secondary objectives were to compare longitudinal changes (at 4 and 12 months, and EOT) in the (i) levels of HDM‐sIgG subclasses and ‐sIgE using ImmunoCAP/‐ISAC and/or ELISA (ii) Der p‐reactivity in skin and basophils using skin prick test and basophil activation test (BAT), (iii) sensitization status defined as sIgE‐positivity in skin and/or serum, and (iv) Der p‐sIgE‐blocking activity using inhibition‐BAT. Results: Eighteen children received HDM‐SLIT (mean age = 4.26 ± 0.37 years, eight females) and 15 placebo (mean age = 4.16 ± 0.59 years, nine females). HDM‐SLIT increased Der p 1‐sIgG levels between baseline and EOT versus placebo (effect size = 3.11 [95% CL 1.36–4.82], p = 0.001). Additional changes induced by HDM‐SLIT were: increased levels of HDM‐sIgG 1 and ‐sIgG 4 , no long‐term increase in HDM‐sIgE levels, reduced Der p‐reactivity in skin and basophils ( p values ≤ 0.05), and blunted development of new sensitizations. Sera from HDM‐SLIT treated individuals displayed blocking activity on basophils ( p values ≤ 0.05). Conclusions: Preventive application of HDM‐SLIT in allergy‐prone children induces immunomodulatory effects early during treatment (elevated sIgG levels with blocking activity and reduced effector cell responses), thereby revealing potential to interfere with allergy development. Trial Registration: EudraCT#2016‐002844‐18